Literature DB >> 27262822

Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP.

Jing Wang1, Min Zhou2, Xiaoyue Wang3, Jingyan Xu2, Bing Chen4, Jian Ouyang2.   

Abstract

BACKGROUND: We assessed the prognostic significance of pretreatment C-reactive protein (CRP) concentration in diffuse large B-cell lymphoma (DLBCL) patients.
METHODS: We retrospectively reviewed 156 patients with newly diagnosed DLBCL. Receiver operating characteristic (ROC) curve analysis was used to generate a cutoff value for CRP. Both log-rank test and multivariable analysis by Cox regression model were used to assess the impact of pretreatment CRP concentrations on the overall survival (OS) and progression-free survival (PFS).
RESULTS: Among those 156 patients enrolled, increased CRP concentration was seen in 51 patients before treatment (≥20mg/l), while the other 105 patients were considered with low CRP concentration. There was no obvious difference in the baseline characteristics between two groups. Increased CRP concentration was significantly associated with poorer OS and PFS than those patients with low CRP concentration (P=0.001 and P=0.000, respectively). Multivariable analysis further showed that CRP concentration was an independent predictor of OS (hazard ratio [HR]=0.47; 95% confidence interval [CI]=0.24-0.92, P=0.028) and PFS (HR=0.37; 95% CI=0.30-0.87, P=0.013).
CONCLUSION: CRP concentration before treatment was an independent prognostic factor in patients with DLBCL.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Diffuse large B-cell lymphoma; Prognosis; Rituximab

Mesh:

Substances:

Year:  2016        PMID: 27262822     DOI: 10.1016/j.cca.2016.05.033

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.

Authors:  Seok Jae Huh; Sung Yong Oh; Suee Lee; Ji Hyun Lee; Sung Hyun Kim; Gyeong-Won Lee; Seok Jin Kim; Won Seog Kim; Ho Sup Lee; Jae-Cheol Jo; Moon Jin Kim; Jung Hye Kwon; Hyo-Jin Kim
Journal:  Int J Hematol       Date:  2019-06-27       Impact factor: 2.490

2.  Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL).

Authors:  Pengcheng Feng; Hongxia Li; Jinhong Pei; Yan Huang; Guixia Li
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

3.  Primary Adrenal Lymphoma: Two Case Series From China.

Authors:  Jinyang Zeng; Fangfang Yan; Yulong Chen; Li Zang; Kang Chen; Zhaohui Lyu; Jingtao Dou; Yiming Mu; Mingzhu Lin; Guoqing Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-28       Impact factor: 5.555

4.  Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.

Authors:  Jing Wang; Min Zhou; Jing-Yan Xu; Yong-Gong Yang; Qi-Guo Zhang; Rong-Fu Zhou; Bing Chen; Jian Ouyang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

5.  Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.

Authors:  Jing-Song He; Xi Chen; Guo-Qing Wei; Jie Sun; Wei-Yan Zheng; Ji-Min Shi; Wen-Jun Wu; Yi Zhao; Gao-Feng Zheng; He Huang; Zhen Cai
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.